Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and neck squamous cell carcinoma.

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Pembrolizumab alone or in combination with chemotherapy can provide long-term benefits over chemotherapy alone in recurrent or metastatic HNSCC, data suggest.

Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in ...

New data presented at AACR supports adding pembrolizumab before and after surgery in patients with newly diagnosed locally ...

Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

Using ctDNA test results to guide adjuvant treatment with pembrolizumab can provide benefits in patients with dMMR solid tumors, data suggest.

This retrospective analysis included 102 patients with advanced RCC treated with either cabozantinib + nivolumab or lenvatinib + pembrolizumab as first-line therapy at Tokyo Women's Medical University ...

Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

Summit Therapeutics Inc. is currently enrolling patients in the Harmoni-7 study, a multiregional Phase III clinical trial ...